ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1709 • ACR Convergence 2022

    Role of Corneal Langerhans Dendritic Cells in Lupus Keratitis

    Ram Singh1 and Angel Gutierrez2, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Patients with lupus and other systemic autoimmune diseases develop ocular surface inflammation that is sometimes severe and debilitating. Pathogenesis of autoimmune keratitis remains unclear.…
  • Abstract Number: 1736 • ACR Convergence 2022

    IL-23 Signaling Induces Autoimmune Disease Genes in Mucosal-Associated Invariant T Cells

    Tharshana Stephen1, Ambre Dangien1, Claire Leloup1, Ikram Mezghiche1, Laetitia Camard1, Hanan Yahia-Cherbal1, Vincent Guillemot2, Natalia Pietrosemoli1, Hélène Lopez-Maestre1, Julie Marsande1, Milena Hasan1, Dan Cua3, Anne Fourie4, Carrie Greving5, Raphaelle Parker6, Barbara Joyce Shaikh7, Bénédicte Oulès8, Sarah Guégan8, Sélim Aractingi8, Elisabetta Bianchi1 and Lars Rogge1, 1Institut Pasteur, Paris, France, 2Institut Pasteur, Paris, Ile-de-France, France, 3Janssen Research and Development, LLC, Spring House, PA, 4Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA, 5Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, 6Janssen Research & Development, Janssen-Cilag, Paris, France, 7Janssen Research & Development, LLC, San Diego, CA, 8Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Genome-wide association studies and mouse models of autoimmune disease have demonstrated an important role of the IL-23 signaling pathway in the pathogenesis of axial…
  • Abstract Number: 1734 • ACR Convergence 2022

    Identification of Sjögren’s Disease-Associated T Cell Receptors Through Deep Sequencing and Single-Cell Transcriptomics

    Ananth Aditya Jupudi1, Michelle Joachims1, Christina Lawrence1, Charmaine Lopez-Davis1, Bhuwan Khatri1, Astrid Rasmussen1, Lida Radfar2, Kiely Grundahl1, R. Hal Scofield2, Judith James1, Joel Guthridge1, Christopher Lessard1, Linda F. Thompson1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Sjögren's disease (SjD) is a chronic rheumatic autoimmune disorder that primarily targets the lacrimal and salivary glands (SG) resulting in dry eyes and dry…
  • Abstract Number: 1750 • ACR Convergence 2022

    Association Between Appendicitis and the Risk of Systemic Lupus Erythematosus: A Population-based, Case-control Study

    Yun-Wen Chen, Taichung Veterans General Hospital, Taichung, Taiwan

    Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by diverse clinical manifestations. The risk factors of SLE included genetic factors and environmental…
  • Abstract Number: 1755 • ACR Convergence 2022

    Improving Quality of Life Through Connection: A Scoping Review of Peer Coaching Interventions in the Field of Rheumatology

    Megan Creasman1, Mackenzie Brown2, Yuliana Domínguez Páez3, Michelle Demetres4, Monika Safford4 and Iris Navarro-Millan4, 1NYP-Weill Cornell, New York, NY, 2Weill Cornell Medicine, Brooklyn, NY, 3Weill Cornell Medicine, Bronx, NY, 4Weill Cornell Medicine, New York, NY

    Background/Purpose: Peer coaches are lay individuals providing health education and behavior change interventions, and often have the same condition as the person that they are…
  • Abstract Number: 1728 • ACR Convergence 2022

    Increased Frequency of Highly Differentiated T Effector Memory Cells Re-expressing CD45RA (Temra) and Cytomegalovirus Seropositivity Are Associated with Persistent Disease Specifically Refractory to Anti-TNF Therapy in Rheumatoid Arthritis

    Su-Ann Yeoh, James Kimpton, Muhammad Shipa, Eleanor Hawkins, Arne Akbar and Michael Ehrenstein, University College London, London, United Kingdom

    Background/Purpose: Enrichment of highly differentiated T cells have been reported in rheumatoid arthritis (RA) patients compared to healthy individuals. The role of highly differentiated T…
  • Abstract Number: 1752 • ACR Convergence 2022

    Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER

    Isabel Castrejon1, Juan Molina2, Carolina Perez-Garcia3, Paloma Vela-Casampere4, Cesar Diaz-Torne5, Cristina Bohorquez6, Juan Maria Blanco-Madrigal7 and Fernando Sanchez-Alonso8, 1Hospital Universitario Gregorio Marañón, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Department of Rheumatology, Hospital del Mar, Barcelona, Spain, 4Hospital General Universitario Alicante, Alicante, Spain, 5Department of Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 6University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, 7Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, 8Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

    Background/Purpose: Extensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk…
  • Abstract Number: 1751 • ACR Convergence 2022

    Diagnosing the Cardiovascular Risk of VIOXX: A Place for Rofecoxib in Pain Management

    Judith Boice, Mark Corrigan and Bradford Sippy, Tremeau Pharmaceuticals, Inc, Concord, MA

    Background/Purpose: Traditional NSAIDs (tNSAIDs) are effective in treating arthritis pain but can be limited by GI adverse events and general bleeding related to platelet inhibition.…
  • Abstract Number: 1631 • ACR Convergence 2022

    Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells

    Ken Yasaka1, Tomohide Yamazaki2, Hiroko Sato1, Tsuyoshi Shirai1, Hiroshi Fujii1, Tomonori Ishii3 and Hideo Harigae4, 1Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, 2SBI Biotech, Tokyo, Japan, 3Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, 4Department of Hematology, Tohoku University Hospital, Sendai, Japan

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with…
  • Abstract Number: 1689 • ACR Convergence 2022

    Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans

    Ramadan Ali1, Miela Zahavi2, Christine Rysenga1, Cyrus Sarosh3, Claire Hoy1, Kristen Demoruelle4 and Jason S Knight5, 1University of Michigan, Ann Arbor, MI, 2Universtiy of Michigan, Ann Arbor, MI, 3University of Michigan, Temperance, MI, 4University of Colorado Anschutz Medical Campus, Aurora, CO, 5University of Michigan, Division of Rheumatology, Ann Arbor, MI

    Background/Purpose: It has previously been reported that 6-gingerol, the most abundant phytochemical in ginger root, inhibits neutrophil phosphodiesterase activity and thereby counteracts neutrophil hyperactivity in…
  • Abstract Number: 1749 • ACR Convergence 2022

    Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis

    Eddie James1, Cliff Rims2, Sylvia Posso2, Jeffrey Carlin3, William Kwok2, Shao-En Ong4 and Jane Buckner1, 1Benaroya Research Institute at Virginia Mason, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3Virginia Mason Medical Center, Seattle, WA, 4University of Washington, Seattle, WA

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease in which citrullinated self-antigens are recognized by anti-citrullinated protein antibodies (ACPA) and T cells. ACPA are a…
  • Abstract Number: 1697 • ACR Convergence 2022

    Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE

    Anne Troldborg1, Mads Lamm Larsen1, Erik J.M. Toonen2, Lisa Hurler3, Zoltan Prohaszka3, László Cervenak3, Annette Gudmann Hansen4 and Steffen Thiel4, 1Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 2Hycult Biotech, Arnhem-Nijmegen, Netherlands, 3Semmelweis University, Budapest, Hungary, 4Aarhus University, Aarhus, Denmark

    Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…
  • Abstract Number: 1634 • ACR Convergence 2022

    Association of Ultra-processed Food Intake with Risk of Systemic Lupus Erythematosus in Women

    Sinara Laurini Rossato1, Chun-Han Lo2, Medha Barbhaiya3, Jeffrey Sparks4, Neha Khandpur5, Susan Malspeis6, Kazuki Yoshida6, Walter C. Willett7 and Karen Costenbader6, 1Universidade Federal de Uberlândia, Uberlândia, Brazil, 2Kirk Kerkorian School of Medicine at UNLV, Las Vegas, 3Hospital for Special Surgery, New York, NY, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Harvard TH Chan School of Public Health, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Harvard TH Chan School of Public Health, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Antioxidants and vitamins present in unprocessed foods may protect against development of systemic lupus erythematosus (SLE) whereas ultra-processed foods (UPFs) remove these nutrients, adding…
  • Abstract Number: 1562 • ACR Convergence 2022

    Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification

    Yeliz Yagiz Ozogul1, Yesim Ozguler2, Didar Ucar3, Ugur Uygunoglu4, Zekayi Kutlubay5, Vedat Hamuryudan6 and gulen Hatemi7, 1Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, 3Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Neurology, Istanbul, Turkey, 5Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Dermatology, Istanbul, Turkey, 6Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 7Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Damage accrual in Behçet syndrome (BS) may progress over the years and an index that can be scored using retrospective data may be useful…
  • Abstract Number: 1417 • ACR Convergence 2022

    Clinical and Demographic Characteristics of Patients with RF+/ACPA+ RA and First-Line TNF Inhibitor versus Abatacept Treatment Choice in Real-World Clinical Practice

    Gordon Lam1, Hanke Zheng2, Emily Bland3, Vardhaman Patel4, Laetitia N’Dri5, Parisa Asgarisabet3, Keith Wittstock4, Cherrishe Brown-Bickerstaff3, Mark Chaballa2, Bruce Feinberg3, Vadim Khaychuk6 and Andrew J Klink3, 1Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 2Bristol Myers Squibb, Princeton, NJ, 3Cardinal Health, Dublin, OH, 4Bristol Myers Squibb, Lawrence Township, NJ, 5Bristol Myers Squibb, Princeton, 6Bristol Myers Squibb, Pennington, MA

    Background/Purpose: Early intensive treatment (tx) is an accepted paradigm in the tx of patients (pts) with RA with poor prognostic factors (eg, RF/ACPA seropositivity); however,…
  • « Previous Page
  • 1
  • …
  • 398
  • 399
  • 400
  • 401
  • 402
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology